AGENDA ITEM | PRESIDER/PRESENTER(s)
--- | ---
**Wednesday, February 27**
8:00 | Welcome & Introductions | Dr. Jose Romero (ACIP Chair)  
Dr. Amanda Cohn (ACIP Executive Secretary; CDC)

8:20 | Japanese Encephalitis Vaccine | Dr. Chip Walter (ACIP, WG Chair)  
Dr. Susan Hills (CDC/NCEZID)

- Introduction
- Background and review
- Updated recommendations for U.S. travelers
- Accelerated primary series in adults
- Booster dose recommendations

8:30 | Break

9:20 | Anthrax Vaccines | Dr. David Stephens (ACIP, WG Chair)  
Dr. William Bower (CDC/NCEZID)

- Introduction
- AV7909 (NuThrax)
- Preexposure AVA booster dose interval

9:30 | Break

10:30 | Influenza Vaccines | Dr. Chip Walter  
Ms. Lynnette Brammer (CDC/NCIRD)  
Dr. Brendan Flannery (CDC/NCEZID)  
Dr. Gregg Sylvester (Seqirus)  
Dr. James Donahue (Marshfield Clinic)  
Dr. Lisa Grohskopf (CDC/NCIRD)

- Introduction
- Surveillance update
- VE update
- Afluria quadrivalent for children aged 6 through 59 months
- Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink
- Summary and work group considerations

12:00 | Lunch

1:00 | Human Papillomavirus Vaccines | Dr. Peter Szilagyi (ACIP, WG Chair)  
Dr. Lauri Markowitz (CDC/NCEZID)  
Dr. Marc Brisson (Laval University)  
Dr. Harrell Chesson (CDC/NCHSTP)  
Dr. Nancy McClung (CDC/NCIRD)  
Dr. Elissa Meites (CDC/NCIRD)  
Dr. Lauri Markowitz (CDC/NCIRD)

- Introduction
- Overview and background
- Impact and cost effectiveness of mid-adult HPV vaccination
- Overview of health economic results from 4 modeling groups
- Mid-adult HPV vaccination: patient values and acceptability
- Program and vaccine provider surveys
- Work group considerations

2:30 | Break

2:40 | Combination Vaccines | Dr. Kelly Moore (ACIP, WG Chair)  
Dr. Andrew Lee (Merck)  
Dr. Laura Hammitt (Johns Hopkins University)  
Dr. Sara Oliver (CDC/NCIRD)

- Introduction
- Immunogenicity and safety of a pediatric hexavalent vaccine
- Hib vaccines in AI/AN population
- Summary, review of work group considerations

3:30 | Break

3:40 | Public Comment

4:55 | Break

5:00 | VOTES | Dr. Susan Hills (CDC/NCEZID)  
Dr. William Bower (CDC/NCEZID)

- Japanese Encephalitis Vaccine
- Anthrax Vaccines

5:30 | Adjourn
Thursday, February 28

8:00 Agency Updates & Unfinished Business
CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO
Dr. Nancy Messonnier (CDC/NCIRD); Ex Officio Members

8:30 Pneumococcal Vaccines
Introduction
PCV13 direct and indirect effects on serotype 3 disease
PCV13 direct effects on pneumonia hospitalizations in adults
Comparison of economic analyses of PCV13 use among adults ≥65 years old
GRADE and Evidence to Recommendations (EtR) for PCV13 use among adults ≥65 years old in the context of indirect effects experience to date
Dr. Grace Lee (ACIP, WG Chair)
Dr. Tamara Pilishvili (CDC/NCIRD)
Dr. Fernanda Lessa (CDC/NCIRD)
Dr. Andrew Leidner (CDC/NCIRD)
Dr. Almea Matanock (CDC/NCIRD)

10:30 Break

10:40 Meningococcal Vaccines
Introduction
Immunogenicity and safety of a MenB-FHbp booster dose
Immunogenicity and safety of a MenB-4C booster dose
GRADE and Evidence to Recommendations Framework for MenB booster doses
Work Group interpretation of data, considerations, and next steps
Dr. David Stephens (ACIP, WG Chair)
Dr. Paul Balmer (Pfizer)
Dr. Phil Watson (GSK)
Dr. Catherine Bozio (CDC/NCIRD)
Dr. Sarah Mbaeyi (CDC/NCIRD)

11:55 Lunch

1:00 Zoster Vaccines
Introduction
Zoster vaccine uptake and supply
RZV safety update
Dr. Kelly Moore (ACIP, WG Chair)
Dr. Kathleen Dooling (CDC/NCIRD)
Dr. Tom Shimabukuro (CDC/NCEZID)

1:40 Hepatitis Vaccines
Introduction
Background: HepA vaccines and persons with HIV infection
GRADE: Use of HepA vaccines among persons with HIV infection
Evidence to Recommendation Framework: Use of HepA vaccines among persons with HIV infection
Dr. Kelly Moore (ACIP, WG Chair)
Dr. Mark Weng (CDC/NCHHSTP)
Ms. Alaya Koneru (CDC/NCHHSTP)
Dr. Mark Weng (CDC/NCHHSTP)

2:35 Vaccine Supply

2:40 Adjourn

Acronyms
AI/AN American Indian/Alaska Native
AVA Anthrax vaccine absorbed
CDC Centers for Disease Control & Prevention
CMS Centers for Medicare and Medicaid Services
DoD Department of Defense
DVA Department of Veterans Affairs
EtR Evidence to Recommendations Framework
FDA Food and Drug Administration
GRADE Grading of Recommendations Assessment, Development and Evaluation
Hib Haemophilus influenzae type b
HRSA Health Resources and Services Administration
IHS Indian Health Service
MenB Serogroup B meningococcal vaccine
NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NVPO National Vaccine Program Office
PCV13 13-valent pneumococcal conjugate vaccine
RZV Recombinant zoster vaccine
WG Work Group

This document has been archived for historical purposes. (2/25/2019)